

GENETICS

DOWN SYNDROME – CURRENT PERSPECTIVES

***Sakshi Yadav**

****Neerja Gupta**

*****Madhulika Kabra**

Abstract: *Down syndrome, identified as a cause of intellectual disability, still remains an area of research in view of the complexity and co-morbidities though molecular mechanisms causing phenotypic expression are being better understood. These patients require multidisciplinary care with significantly improved quality of life. This article discusses the newer concepts in pathogenesis, management of uncommon comorbidities, prevention and recent research in therapy of Down syndrome.*

Keywords: *Down syndrome, Neurological morbidities, Molecular mechanisms.*

Points to Remember

- *Molecular mechanisms for phenotypic expression of DS.*
- *Management of uncommon morbidities.*
- *Current research in therapy.*

References

1. Kaur A, Singh JR. Chromosomal Abnormalities: Genetic Disease Burden in India. *Int J Hum Genet* 2010; 10:1-14.
2. Jayalakshamma, Margaret M, Amudha S, Tilak P, Devi R, Rajangam S. Cytogenetic analysis in Down syndrome. *Int J Hum Genet* 2010;10: 95-99.
3. Roizen NJ, Patterson D. Down's syndrome. *Lancet* (London, England) 2003; 361(9365):1281-1289.
4. Antonarakis SE. Down syndrome and the complexity of genome dosage imbalance. *Nat Rev Genet* 2017; 18:147-163.
5. Hattori M, Fujiyama A, Taylor TD, Watanabe H, Yada T, Park HS, et al. The DNA sequence of human chromosome 21. *Nature* 2000; 405(6784):311-319.
6. Antonarakis SE. Down syndrome and the complexity of genome dosage imbalance. *Nat Rev Genet* 2017; 18(3):147-163.
7. Letourneau A, Santoni FA, Bonilla X, Sailani MR, Gonzalez D, Kind J, et al. Domains of genome-wide gene expression dysregulation in Down's syndrome. *Nature* 2014; 508(7496):345-350.
8. Vis JC, Duffels MGJ, Winter MM, Weijerman ME, Cobben JM, Huisman SA, et al. Down syndrome: a cardiovascular perspective. *J Intellect Disabil Res* 2009; 53(5):419-425.
9. Benhaourech S, Drighil A, Hammiri AE. Congenital heart disease and Down syndrome: various aspects of a confirmed association. *Cardiovasc J Afr* 2016; 27: 287-290.
10. Weijerman ME, de Winter JP. Clinical practice. The care of children with Down syndrome. *Eur J Pediatr* 2010; 169(12):1445-1452.
11. Agarwal Gupta N, Kabra M. Diagnosis and Management of Down Syndrome. *Indian J Pediatr* 2014; 81(6):560-567.
12. Bull MJ. Health supervision for children with Down syndrome. *Pediatrics* 2011; 128(2):393-406.

* Senior Resident - DM Medical Genetics

** Assistant Professor

*** Professor,
Division of Genetics,
Department of Pediatrics,
All India Institute of Medical Sciences,
New Delhi
email: madhulikakabra@hotmail.com

13. Choi JK. Hematopoietic Disorders in Down Syndrome. *Int J Clin Exp Pathol* 2008; 1:387-395.
14. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. *Am J Gastroenterol* 2013; 108(5):656-676.
15. Storm W. Prevalence and diagnostic significance of gliadin antibodies in children with Down syndrome. *Eur J Pediatr* 1990; 149(12):833-834.
16. Bhat AS, Chaturvedi MK, Saini S, Bhatnagar S, Gupta N, Sapra S, et al. Prevalence of Celiac Disease in Indian Children with Down Syndrome and its Clinical and Laboratory Predictors. *Indian J Pediatr* 2013; 80(2):114-117.
17. Aberg A-K, Olcen P. Serologic screening for celiac disease in children: a comparison between established assays and tests with deamidated gliadin-derived peptides plus conjugates for both IgA and IgG antibodies. *APMIS* 2009; 117(11):808-813.
18. Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. *J Pediatr Gastroenterol Nutr* 2012; 54(1):136-160.
19. Madan V, Williams J, Lear JT. Dermatological manifestations of Down's syndrome. *Clin Exp Dermatol* 2006; 31(5):623-629.
20. Carter DM, Jegasothy B V. Alopecia areata and Down syndrome. *Arch Dermatol* 1976; 112(10):1397-1399.
21. Schepis C, Barone C, Siragusa M, Pettinato R, Romano C. An Updated Survey on Skin Conditions in Down Syndrome. *Dermatology* 2002; 205(3):234-238.
22. Molloy CA, Murray DS, Kinsman A, Castillo H, Mitchell T, Hickey FJ, et al. Differences in the clinical presentation of Trisomy 21 with and without autism. *J Intellect Disabil Res* 2009; 53(2):143-151.
23. Ji NY, Capone GT, Kaufmann WE. Autism spectrum disorder in Down syndrome: cluster analysis of Aberrant Behaviour Checklist data supports diagnosis. *J Intellect Disabil Res* 2011; 55(11):1064-1077.
24. DiGuseppi C, Hepburn S, Davis JM, Fidler DJ, Hartway S, Lee NR, et al. Screening for Autism Spectrum Disorders in Children With Down Syndrome: Population Prevalence and Screening Test Characteristics. *J Dev Behav Pediatr* 2010; 31(3):181-191.
25. Carter JC, Capone GT, Gray RM, Cox CS, Kaufmann WE. Autistic-spectrum disorders in Down syndrome: further delineation and distinction from other behavioral abnormalities. *Am J Med Genet B Neuropsychiatr Genet* 2007; 144B(1):87-94.
26. Hepburn S, Philofsky A, Fidler DJ, Rogers S. Autism symptoms in toddlers with Down syndrome: a descriptive study. *J Appl Res Intellect Disabil* 2008; 21(1):48-57.
27. Huerta M, Bishop SL, Duncan A, Hus V, Lord C. Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders. *Am J Psychiatry* 2012; 169(10):1056-1064.
28. Rachubinski AL, Hepburn S, Elias ER, Gardiner K, Shaikh TH. The co-occurrence of Down syndrome and autism spectrum disorder: is it because of additional genetic variations? *Prenat Diagn* 2017; 37(1):31-36.
29. Gaete B, Mellado C, Hernandez M. [Prevalence of neurological disorders among children with Down syndrome]. *Rev Med Chil* 2012; 140(2):214-218.
30. Johannsen P, Christensen JE, Goldstein H, Nielsen VK, Mai J. Epilepsy in Down syndrome-prevalence in three age groups. *Seizure* 1996; 5(2):121-125.
31. Arya R, Kabra M, Gulati S. Epilepsy in children with Down syndrome. *Epileptic Disord* 2011; 13(1):1-7.
32. Stafstrom CE. Epilepsy in Down syndrome: clinical aspects and possible mechanisms. *Am J Ment Retard* 1993; 98 Suppl: 12-26.
33. Barca D, Tarta-Arsene O, Dica A, Iliescu C, Budisteanu M, Motoescu C, et al. Intellectual Disability and Epilepsy in Down Syndrome. *Maedica (Buchar)* 2014; 9(4):344-350.
34. Petkovic M, Dietschy T, Freire R, Jiao R, Stagljar I. The human Rothmund-Thomson syndrome gene product, RECQL4, localizes to distinct nuclear foci that coincide with proteins involved in the maintenance of genome stability. *J Cell Sci* 2005; 118(Pt 18):4261-4269.
35. Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VLJ, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. *Nat Rev Neurosci* 2015; 16:564-574.
36. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. *Exp Neurol* 1998; 150(2):296-304.
37. Wiseman FK, Alford KA, Tybulewicz VLJ, Fisher EMC. Down syndrome-recent progress and future prospects. *Hum Mol Genet* 2009; 18(R1):R75-83.
38. Kelley CM, Ash JA, Powers BE, Velazquez R, Alldred MJ, Ikonovic MD, et al. Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome. *Curr Alzheimer Res* 2016; 13(1):84-96.
39. Asim A, Kumar A, Muthuswamy S, Jain S, Agarwal S. "Down syndrome: an insight of the disease". *J Biomed Sci* 2015; 22(1):41.
40. Mezei G, Sudan M, Izraeli S, Kheifets L. Epidemiology of childhood leukemia in the presence and absence of Down syndrome. *Cancer Epidemiol* 2014; 38(5):479-489.
41. Gruber TA, Downing JR. The biology of pediatric acute megakaryoblastic leukemia. *Blood* 2015; 126(8):943-949.

42. Khan I, Malinge S, Crispino JD. Myeloid Leukemia in Down Syndrome. *Crit Rev Oncog* 2011; 16(1–2):25-36.
43. Hasle H, Friedman JM, Olsen JH, Rasmussen SA. Low risk of solid tumors in persons with Down syndrome. *Genet Med* 2016; 18:1151-1157.
44. Pradhan M, Dalal A, Khan F, Agrawal S. Fertility in men with Down syndrome: a case report. *Fertil Steril* 2006; 86(6):1765.e1-1765.e3.
45. Livingstone N, Hanratty J, McShane R, Macdonald G. Pharmacological interventions for cognitive decline in people with Down syndrome. *Cochrane database Syst Rev* 2015; (10):CD011546.
46. Jiang J, Jing Y, Cost GJ, Chiang J-C, Kolpa HJ, Cotton AM, et al. Translating dosage compensation to trisomy 21. *Nature* 2013; 500:296-300.
47. Li LB, Chang K-H, Wang P-R, Hirata RK, Papayannopoulou T, Russell DW. Trisomy correction in Down syndrome induced pluripotent stem cells. *Cell Stem Cell*. 2012; 11(5):615-619.
48. Ani C, Grantham-McGregor S, Muller D. Nutritional supplementation in Down syndrome: theoretical considerations and current status. *Dev Med & Child Neurol* 2000; 42(3):207-213.
49. Shichiri M, Yoshida Y, Ishida N, Hagihara Y, Iwahashi H, Tamai H, et al. alpha-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. *Free Radic Biol Med* 2011; 50(12):1801-1811.
50. Lockrow J, Prakasam A, Huang P, Bimonte-Nelson H, Sambamurti K, Granholm A-C. Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. *Exp Neurol*. 2009; 216(2):278-289.
51. Ellis JM, Tan HK, Gilbert RE, Muller DPR, Henley W, Moy R, et al. Supplementation with antioxidants and folic acid for children with Down's syndrome: randomised controlled trial. *BMJ* 2008; 336(7644):594-597.
52. Parisotto EB, Garlet TR, Cavalli VL de LO, Zamoner A, da Rosa JS, Bastos J, et al. Antioxidant intervention attenuates oxidative stress in children and teenagers with Down syndrome. *Res Dev Disabil [Internet]* 2014; 35(6):1228-36. Available from: <http://www.sciencedirect.com/science/article/pii/S089142221400105X>. Accessed on 14.02.2019.
53. Cuckle HS. Primary prevention of Down's syndrome. *Int J Med Sci* 2005; 2:p93-99.
54. Boue A, Gallano P. A collaborative study of the segregation of inherited chromosome structural rearrangements in 1356 prenatal diagnoses. *Prenat Diagn* 1984 Spring; 4 Spec No:45-67.
55. Practice Bulletin No. 163 Summary: Screening for Fetal Aneuploidy. *Obstet Gynecol* 2016; 127(5):979-981.
56. Kagan KO, Wright D, Baker A, Sahota D, Nicolaidis KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. *Ultrasound Obstet Gynecol* 2008; 31(6):618-624.
57. Spencer K, Spencer CE, Power M, Dawson C, Nicolaidis KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. *BJOG* 2003; 110(3):281-286.
58. Nicolaidis KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. *Ultrasound Obstet Gynecol* 2005; 25(3):221-226.
59. Cuckle H. Biochemical screening for Down syndrome. *Eur J Obstet Gynecol Reprod Biol* 2000; 92(1):97-101.
60. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. *BMJ* 1988 Oct; 297(6653):883-887.
61. Park SY, Jang IA, Lee MA, Kim YJ, Chun SH, Park MH. Screening for chromosomal abnormalities using combined test in the first trimester of pregnancy. *Obstetrics & Gynecology Science* 2016; 59:357-366.
62. Edithy Cheng. Prenatal Diagnosis. In: Avery's diseases of the newborn. 10th edn, Christine A Gleason, Sandra E Juul (Eds). Elsevier, Philadelphia 2018; pp190-200.
63. Lau TK, Chen F, Pan X, Pooh RK, Jiang F, Li Y, et al. Noninvasive prenatal diagnosis of common fetal chromosomal aneuploidies by maternal plasma DNA sequencing. *J Matern Fetal Neonatal Med* 2012; 25(8):1370-1374.
64. Committee Opinion No. 640: Cell-Free DNA Screening For Fetal Aneuploidy. *Obstet Gynecol* 2015; 126(3):e31-37.
65. Taylor-Phillips S, Freeman K, Geppert J, Agbebiyi A, Uthman OA, Madan J, et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. *BMJ Open* 2016; 6(1):e010002.
66. Ulbjerg N. No-call non-invasive prenatal testing gives important information. *BJOG* 2018; 125(7):856.
67. Data from Committee on Genetics; Health supervision for children with Down syndrome *Pediatrics* 107: 442-449. 2001; and Baum R, Spader m, Nash PL, et al. Primary care of children and adolescents with Down syndrome; an update, *Curr Probl Pediatr Adolesc Health Care* 38:235-268. 2008.